Histone deacetylase inhibitors in the treatment of cancer: overview and perspectives

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

References

• 1  Allfrey VG, Faulkner R, Mirsky AE. Acetylation and methylation of histones and their possible role in the regulation of RNA synthesis. Proc. Natl Acad. Sci. USA51,786–794 (1964).
  Medline CASGoogle Scholar
• 2  Kleff S, Andrulis ED, Anderson CW, Sternglanz R. Identification of a gene encoding a yeast historic H4 acetyltransferase. J. Biol. Chem.270,24674–24677 (1995).
  Medline CASGoogle Scholar
• 3  Brownell JE, Zhou J, Ranalli T et al. Tetrahymena histone acetyltransferase A: a homolog to yeast Gcn5p linking histone acetylation to gene activation. Cell84,843–851 (1996).
  Medline CASGoogle Scholar
• 4  Taunton J, Hassig CA, Schreiber SL. A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science272,408–411 (1996).
  Medline CASGoogle Scholar
• 5  Tanner KG, Landry J, Sternglanz R, Denu JM. Silent information regulator 2 family of NAD- dependent histone/protein deacetylases generates a unique product, 1-O-acetyl-ADP-ribose. Proc. Natl Acad. Sci. USA97,14178–14182 (2000).
  Medline CASGoogle Scholar
• 6  Martin M, Kettmann R, Dequiedt F. Class IIa histone deacetylases: regulating the regulators. Oncogene26,5450–5467 (2007).
  Medline CASGoogle Scholar
• 7  Grant S, Easley C, Kirkpatrick P. Vorinostat. Nat. Rev. Drug Discov.6,21–22 (2007).
  Medline CASGoogle Scholar
• 8  Breslow M. Dimethyl sulfoxide to vorinostat development of this histone deacetylase inhibitor as an anticancer drug. Nat. Biotechnol.25,84–90 (2007).
  MedlineGoogle Scholar
• 9  VanderMolen KM, McCulloch W, Pearce CJ, Oberlies NH. Romidepsin: a natural product recently approved for cutaneous T-cell lymphoma. J. Antibiot.64,525–531 (2011).
  Medline CASGoogle Scholar
• 10  Boumber Y, Issa J-PJ. Epigenetics in cancer: what’s the future? Oncology25,1–13 (2011).
  Google Scholar
• 11  Biel M, Wascholowski V, Giannis A. Epigenetic – an epicenter of gene regulation: histones and histone-modifying enzymes. Angew. Chem. Int. Ed. Engl.44,3186–3216 (2005).
  Medline CASGoogle Scholar
• 12  Mai A, Massa S, Rotili D et al. Histone deacetylation in epigenetics: an attractive target for anticancer therapy. Med. Res. Rev.3,261–309 (2005).
  Google Scholar
• 13  Rodriquez M, Aquino M, Bruno I, De Martino G, Taddei M, Gomez-Paloma L. Chemistry and biology of chromatin remodeling agents: state of art and future perspective of HDAC inhibitors. Curr. Med. Chem.13,1119–1139 (2006).
  Medline CASGoogle Scholar
• 14  Petrella A, Fontanella B, Carratù A, Bizzarro V, Rodriquez M, Parente L. Histone deacetylase inhibitors in the treatment of hematological malignancies. Mini Rev. Med. Chem.11,519–527 (2011).
  Medline CASGoogle Scholar
• 15  Kristeleit R, Stimson L, Workman P, Aherne W. Histone modification enzymes: novel targets for cancer drugs. Expert Opin. Emerg. Drugs.9,135–154 (2004).
  Medline CASGoogle Scholar
• 16  Marks PA, Richon VM, Miller TA, Kelly WK. Histone deacetylase inhibitors: new targeted anticancer drugs. In: Cancer: Principles and Practice of Oncology (7th Edition). DeVita VT Jr, Hellman S, Rosenberg SA (Eds). Lippincott Williams & Wilkins, Philadelphia, PA, USA, 439–445 (2005).
  Google Scholar
• 17  Peserico A, Simone C. Physical and functional HAT/HDAC interplay regulates protein acetylation balance. J. Biomed. Biotechnol.371832 (2011).
  MedlineGoogle Scholar
• 18  Yang XJ, Seto E. The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat. Rev. Mol. Cell Biol.9,206–218 (2008).
  Medline CASGoogle Scholar
• 19  de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem. J.370,737–749 (2003).
  Medline CASGoogle Scholar
• 20  Gregoretti IV, Lee YM, Goodson HV. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J. Mol. Biol.338,17–31 (2004).
  Medline CASGoogle Scholar
• 21  Marks PA. The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. Expert Opin. Investig. Drugs19,1049–1066 (2010).▪ Focuses on the mechanisms of action of the histone deacetylase inhibitors (HDACis), as well as the clinical studies and the advantage of HDACis when they are used in combination with cytotoxic or other targeted anticancer agents.
  Medline CASGoogle Scholar
• 22  Yang XJ, Grégoire S. Class II histone deacetylases: from sequence to function, regulation and clinical implication. Mol. Cell. Biol.25,2873–2884 (2005).
  Medline CASGoogle Scholar
• 23  Glozak MA, Sengupta N, Zhang X, Seto E. Acetylation and deacetylation of non-histone proteins. Gene363,15–23 (2005).
  Medline CASGoogle Scholar
• 24  Kim SC, Sprung R, Chen Y et al. Substrates and functional diversity of lysine acetylation revealed by a proteomics survey. Mol. Cell23,607–618 (2006).
  Medline CASGoogle Scholar
• 25  Witt O, Deubzer HE, Milde Y, Oehme I. HDAC family: what are the cancer relevant targets? Cancer Lett.277,8–21 (2009).
  Medline CASGoogle Scholar
• 26  Lemoine M, Younes A. Histone deacetylase inhibitors in the treatment of lymphoma. Discov. Med.10,462–470 (2010).
  MedlineGoogle Scholar
• 27  Dokmanovic M, Clarke C, Marks PA. Histone deacetylase inhibitors: overview and perspectives. Mol. Cancer Res.5,981–989 (2007).
  Medline CASGoogle Scholar
• 28  Chang S, McKinsey TA, Zhang CL, Richardson JA, Hill JA, Olson EN. Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development. Mol. Cell. Biol.24,8467–8476 (2004).
  Medline CASGoogle Scholar
• 29  McKinsey TA, Olson EN. Cardiac histone acetylation – therapeutic opportunities abound. Trends Genet.20,206–213 (2004).
  Medline CASGoogle Scholar
• 30  McKinsey TA, Olson EN. Toward transcriptional therapies for the failing heart: chemical screens to modulate genes. J. Clin. Invest.115,538–546 (2005).
  Medline CASGoogle Scholar
• 31  Ng HH, Bird A. Histone deacetylases: silencers for hire. Trends Biochem. Sci.25,121–126 (2000).
  Medline CASGoogle Scholar
• 32  Legube G, Trouche D. Regulating histone acetyltransferases and deacetylases. EMBO Reports Rev.4,944–947 (2003).
  Medline CASGoogle Scholar
• 33  Rayman JB, Takahashi Y E2F mediates cell cycle-dependent transcriptional repression in vivo by recruitment of an HDAC1/mSin3B corepressor complex. Genes Dev.16,933–947 (2002).
  Medline CASGoogle Scholar
• 34  Balciunaite E, Spektor A. Pocket protein complexes are recruited to distinct targets in quiescent and proliferating cells. Mol. Cell. Biol.25,8166–8178 (2005).
  Medline CASGoogle Scholar
• 35  Knoepfler PS, Eisenman RN. Sin meets NuRD and other tails of repression. Cell99,447–450 (1999).
  Medline CASGoogle Scholar
• 36  Lunyak VV, Burgess R, Prefontaine GG et al. Corepressor-dependent silencing of chromosomal regions encoding neuronal genes. Science298,1747–1752 (2002).
  Medline CASGoogle Scholar
• 37  Fischle W, Dequiedt F, Hendzel MJ et al. Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/NCoR. Mol. Cell9,45–57 (2002).
  Medline CASGoogle Scholar
• 38  Chan JK, Sun L, Yang XJ, Zhu G, Wu Z. Functional characterization of an amino-terminal region of HDAC4 that possesses MEF2 binding and transcriptional repressive activity. J. Biol. Chem.278,23515–23521 (2003).
  Medline CASGoogle Scholar
• 39  Fischle W, Dequiedt F, Fillion M, Hendzel MJ, Voelter W, Verdin E. Human HDAC7 histone deacetylase activity is associated with HDAC3 in vivo. J. Biol. Chem.276,35826–35835 (2001).
  Medline CASGoogle Scholar
• 40  Lahm A, Paolini C, Pallaoro M et al. Unraveling the Hidden Catalytic Activity of Vertebrate Class IIa Histone Deacetylases. Proc. Natl Acad. Sci. USA104,17335–17340 (2007).
  Medline CASGoogle Scholar
• 41  Hockly E, Richon VM, Woodman B et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington’s disease. Proc. Natl Acad. Sci. USA100,2041–2046 (2003).
  Medline CASGoogle Scholar
• 42  Bottomley MJ, Lo Surdo P, Di Giovine P et al. Structural and functional analysis of the human HDAC4 catalytic domain reveals a regulatory structural zinc-binding domain. J. Biol. Chem.283,26694–26704 (2008).
  Medline CASGoogle Scholar
• 43  Beumer JH, Tawbi H. Role of histone deacetylases and their inhibitors in cancer biology and treatment. Curr. Clin. Pharmacol.5,196–208 (2010).▪ Focuses on the potential of HDACis for cancer therapy with a careful preclinical and clinical evaluation on some HDACis used in solid tumors in combination with chemotherapy. Discusses the biomarker as a useful guide for the rational development of HDACis as anticancer therapy.
  Medline CASGoogle Scholar
• 44  Marquard L, Gjerdrum LM, Christensen IJ, Jensen PB, Sehested M, Ralfkiaer E. Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma. Histopathology53,267–277 (2008).
  Medline CASGoogle Scholar
• 45  Weichert W. HDAC expression and clinical prognosis in human malignancies. Cancer Lett.280,168–176 (2009).
  Medline CASGoogle Scholar
• 46  Taunton J, Collins JL, Schreiber SL. Synthesis of natural and modified trapoxins, useful reagents for exploring histone deacetylase function. J. Am. Chem. Soc.118,10412–10422 (1996).
  CASGoogle Scholar
• 47  Glaser KB, Li J, Pease LJ et al. Differential protein acetylation induced by novel histone deacetylase inhibitors. Biochem. Biophys. Res. Commun.325,683–690 (2004).
  Medline CASGoogle Scholar
• 48  Bertrand P. Inside HDAC with HDAC inhibitors. Eur. J. Med. Chem.45,2095–2116 (2010).
  Medline CASGoogle Scholar
• 49  Yadong C, Huifang L, Wanquan T et al. 3D-QSAR studies of HDACs inhibitors using pharmacophore-based alignment. Eur. J.Med. Chem.44,2868–2876 (2009).
  MedlineGoogle Scholar
• 50  Noureen N, Kalsoom S, Rashid H. Ligand based pharmacophore modelling of anticancer histone deacetylase inhibitors. Afr. J. Biotech.9,3923–3931 (2010).
  CASGoogle Scholar
• 51  Richon VM, Webb Y, Merger R et al. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc. Natl Acad. Sci. USA93,5705–5708 (1996).
  Medline CASGoogle Scholar
• 52  Butler LM, Agus DB, Scher HI et al. Suberoylanilide hydroxamic acid, an in vivo inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res.60,5165–5170 (2000).
  Medline CASGoogle Scholar
• 53  Reuben RC, Wife RL, Breslow R, Rifkind RA, Marks PA. A new group of potent inducers of differentiation in murine erythroleukemia cells. Proc. Natl Acad. Sci. USA73,862–866 (1976).
  Medline CASGoogle Scholar
• 54  Su GH, Sohn TA, Ryu B, Kern SE. A novel histone deacetylase inhibitor identified by high-throughput transcriptional screening of compound library. Cancer Res.60,3137–3142 (2000).
  Medline CASGoogle Scholar
• 55  Wong JC, Hong R, Schreiber SL. Structural biasing elements for in-cell histone deacetylase paralog selectivity. J. Am. Chem. Soc.125,5586–5587 (2003).
  Medline CASGoogle Scholar
• 56  Hanessian S, Vinci V, Auzzas L, Marzi M, Giannini G. Exploring alternative Zn-binding groups in the design of HDAC inhibitors: squaric acid, N-hydroxylurea and oxazoline analogues of SAHA. Bioorg. Med. Chem. Lett.16,4784–4787 (2006).
  Medline CASGoogle Scholar
• 57  Hanessian S, Auzzas L, Giannini G et al. Omega-alkoxy analogues of SAHA (vorinostat) as inhibitors of HDAC: a study of chain-length and stereochemical dependence. Bioorg. Med. Chem. Lett.17,6261–6265 (2007).
  Medline CASGoogle Scholar
• 58  Kozikowski AP, Tapadar S, Luchini DN, Kim KH, Billadeau DD. Isoxazole moiety in the linker region of HDAC inhibitors adjacent to the Zn-chelating group: effects on the HDAC biology and antiproliferative activity. J. Med. Chem.51,4370–4373 (2008).
  Medline CASGoogle Scholar
• 59  Giannini G, Marzi M, Pezzi R et al. N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase. Bioorg. Med. Chem. Lett.19,2346–2349 (2009).
  Medline CASGoogle Scholar
• 60  Auzzas L, Larsson A, Matera R et al. Non-natural macrocyclic inhibitors of histone deacetylase: design, synthesis and activity. J. Med. Chem.,53,8387–8399 (2010).
  Medline CASGoogle Scholar
• 61  Zhang Y, Fang H, Feng J, Jia Y, Wang X, Xu W. Discovery of a tetrahydroisoquinoline-based hydroxamic acid derivative (ZYJ-34c) as histone deacetylase inhibitor with potent oral antitumor activities. J. Med. Chem.54,5532–5539 (2011).
  Medline CASGoogle Scholar
• 62  Tsuji N, Kobayashi M, Nagashima K, Wakisaka Y, Koizumi K. A new antifungal antibiotic, trichostatin. J. Antibiot.29,1–6 (1976).
  Medline CASGoogle Scholar
• 63  Mori K, Koseki K. Synthesis of trichostatin A, a potent differentiation inducer of Friend-leukemic cells and its antipode. Tetrahedron44,6013–6020 (1988).
  CASGoogle Scholar
• 64  Remiszewski SW, Sambucetti LC, Bair KW et al. N-hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: discovery of NVP-LAQ824. J. Med. Chem.46,4609–4624 (2003).
  Medline CASGoogle Scholar
• 65  Li KW, Wu J, Xing W, Simon JA. Total synthesis of the antitumor depsipeptide FR-901, 228. J. Am. Chem. Soc.118,7237–7238 (1996).
  CASGoogle Scholar
• 66  Furumai R, Matsuyama A, Kobashi N et al. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res.62,4916–4921 (2002).
  Medline CASGoogle Scholar
• 67  Ueda H, Nakajiam H, Hori Y et al. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromabacterium violaceum. J. Antibiot.47,301–310. (1994).
  Medline CASGoogle Scholar
• 68  Closse A, Huguenin R. Isolierung und Strukturaufklärung von Chlamydocin. Helv. Chim. Acta57,533–545 (1974).
  Medline CASGoogle Scholar
• 69  Gross ML, McCrery D, Crow F et al. The structure of the toxin from helminthosporium carbonum. Tetrahedron Lett.23,5381–5384 (1982).
  CASGoogle Scholar
• 70  Umehara K, Nakahara K, Kijoto S et al. Studies on WF-3161, a new antitumor antibiotic. J. Antibiot.36,478–483 (1983).
  Medline CASGoogle Scholar
• 71  Schmidt U, Beutler U, Lieberknecht A. Total synthesis of the antitumor antibiotic WF-3161. Angew. Int. Ed.28,333–334 (1989).
  Google Scholar
• 72  Itazaki H, Nagashima K, Sugita K et al. Isolation and structural elucidation of new cyclotetrapeptides, trapoxins A and B, having detransformation activities as antitumor agents. J. Antibiot.43,1524–1532 (1990).
  Medline CASGoogle Scholar
• 73  Kijima M, Yoshida M, Sugita K, Horinouchi S, Beppu T. Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. J. Biol. Chem.268,22429–22435 (1993).
  Medline CASGoogle Scholar
• 74  Darkin-Rattray SJ, Gurnett AM, Myers RW et al. Apicidin: a novel antiprotozoal agent that inhibits parasite histone deacetylase. Proc. Natl Acad. Sci. USA93,13143–13147 (1996).
  Medline CASGoogle Scholar
• 75  Singh SB, Zink DL, Liesch JM et al. Structure and chemistry of apicidins, a class of novel cyclic tetrapeptides without a terminal α-keto epoxide as inhibitors of histone deacetylase with potent antiprotozoal activities. J. Org. Chem.67,815–825 (2002).
  Medline CASGoogle Scholar
• 76  Colletti SL, Myers RW, Darkin-Rattray SJ et al. Broad spectrum antiprotozoal agents that inhibit histone deacetylase: structure-activity relationships of apicidin. Part 1. Bioorg. Med. Chem. Lett.11,107–111 (2001).
  Medline CASGoogle Scholar
• 77  Colletti SL, Myers R W, Darkin-Rattray SJ et al. Broad spectrum antiprotozoal agents that inhibit histone deacetylase: structure-activity relationships of apicidin. Part 2. Bioorg. Med. Chem. Lett.11,113–117 (2001).
  Medline CASGoogle Scholar
• 78  Mori H, Urano Y, Abe F et al. FR235222, a fungal metabolite, is a novel immunosuppressant that inhibits mammalian histone deacetylase (HDAC). I. Taxonomy, fermentation, isolation and biological activities. J. Antibiot.56,72–79 (2003).
  Medline CASGoogle Scholar
• 79  Xie W, Zou B, Pei D, Ma D. Total synthesis of cyclic tetrapeptide FR235222, a potent immunosuppressant that inhibits mammalian histone deacetylases. Org. Lett.7,2775–2777 (2005).
  Medline CASGoogle Scholar
• 80  Rodriquez M, Terracciano S, Cini E et al. Total synthesis, NMR solution structure, and binding model of the potent histone deacetylase inhibitor FR235222. Angew. Chem. Int. Ed. Engl.45,423–427 (2006).
  Medline CASGoogle Scholar
• 81  Gomez-Paloma L, Bruno I, Cini E et al. Design and synthesis of cyclopeptide analogues of the potent histone deacetylase inhibitor FR235222. ChemMedChem2,1511–1519 (2007).
  Medline CASGoogle Scholar
• 82  Di Micco S, Terracciano S, Bruno I et al. Molecular modeling studies toward the structural optimization of new cyclopeptide-based HDAC inhibitors modeled on the natural product FR235222. Bioorg. Med. Chem.16,8635–8642 (2008).
  Medline CASGoogle Scholar
• 83  Suzuki T. Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives. J. Med. Chem.42,3001–3003 (1999).
  Medline CASGoogle Scholar
• 84  El-Beltagi HM, Martens ACM, Lelieved P, Haroun EA, Hagenbeek A. Acetyldinaline: a new oral cytostatic drug with impressive differential activity against leukemic cells and normal stem cell. Cancer Res.53,3008–3014 (1993).
  Medline CASGoogle Scholar
• 85  Vaisburg A, Bernstein N, Frechette S et al. (2-amino-phenyl)-amides of omega-substituted alkanoic acids as new histone deacetylase inhibitors. Bioorg. Med. Chem Lett.14,283–287 (2004).
  Medline CASGoogle Scholar
• 86  Frey RR, Wada CK, Garland RB et al. Trifluoromethylketones as inhibitors of histone deacetylase. Bioorg. Med. Chem. Lett.12,3443–3447 (2002).
  Medline CASGoogle Scholar
• 87  Vasudevan A, Ji Z, Frey RR et al. Heterocyclic ketones as inhibitors of histone deacetylase. Biooorg. Med. Chem. Lett.13,3909–3913 (2003).
  Medline CASGoogle Scholar
• 88  Galletti P, Quintavalla A, Ventrici C et al. Azetidinones as zinc-binding groups to design selective HDAC8 inhibitors. ChemMedChem4,1991–2001 (2009).
  Medline CASGoogle Scholar
• 89  Botta CB, Cabri W, Cini E et al. Oxime amide as a novel zinc binding group in histone deacetylase inhibitors: synthesis, biological activity and computational evaluation. J. Med. Chem.54,2165–2182 (2011).
  Medline CASGoogle Scholar
• 90  Ungerstedt JS, Sowa Y, Xu WS et al. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc. Natl Acad. Sci. USA102,673–678 (2005).
  Medline CASGoogle Scholar
• 91  Bolden JE, Peart MJ, Ricky W, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov.5,769–784 (2006).
  Medline CASGoogle Scholar
• 92  Van Lint C, Emiliani S, Verdin E. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr.5,245–253 (1996).
  Medline CASGoogle Scholar
• 93  Glaser KB, Staver MJ, Waring JF, Stender J, Ulrich RG, Davidsen SK. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol. Cancer Ther.2,151–163 (2003).
  Medline CASGoogle Scholar
• 94  Richon VM, Sandhoff TW, Rifkind RA, Marks PA. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc. Natl Acad. Sci. USA97,10014–10019 (2000).
  Medline CASGoogle Scholar
• 95  Xu Y. Regulation of p53 responses by posttranslational modifications. Cell Death Diff.10,400–403 (2003).
  Medline CASGoogle Scholar
• 96  Jin YH, Jeon EJ, Li QL et al. Transforming growth factor -beta stimulates p300-dependent RUNX3 acetylation, which inhibits ubiquitination-mediated degradation. J. Biol. Chem.279,29409–29417 (2004).
  Medline CASGoogle Scholar
• 97  Chi XZ, Yang JO, Lee KY et al. RUNX3 suppresses gastric epithelial cell growth by inducing p21(WAF1/Cip1) expression in cooperation with transforming growth factor {beta}-activated SMAD. Mol. Cell. Biol.25,8097–8107. (2005).
  Medline CASGoogle Scholar
• 98  Yano T, Ito K, Fukamachi H et al. The RUNX3 tumor suppressor upregulates Bim in gastric epithelial cells undergoing transforming growth factor betainduced apoptosis. Mol. Cell. Biol.26,4474–4488 (2006).
  Medline CASGoogle Scholar
• 99  Rascle A, Johnston JA, Amati B. Deacetylase activity is required for recruitment of the basal transcription machinery and transactivation by STAT5. Mol. Cell. Biol.23,4162–4173 (2003).
  Medline CASGoogle Scholar
• 100  Wang LG, Ossowski L, Ferrari AC. Androgen receptor level controlled by a suppressor complex lost in an androgen-independent prostate cancer cell line. Oncogene23,5175–5184 (2004).
  Medline CASGoogle Scholar
• 101  Lee EM, Shin S, Cha HJ et al. Suberoylanilide hydroxamic acid (SAHA) changes microRNA expression profiles in A549 human non-small cell lung cancer cells. Int. J. Mol. Med.24,45–50 (2009).
  Medline CASGoogle Scholar
• 102  Burgess A, Ruefli A, Beamish H et al. Histone deacetylase inhibitors specifically kill nonproliferating tumour cells. Oncogene23,6693–6701 (2004).
  Medline CASGoogle Scholar
• 103  Zhang Y, Adachi M, Kawamura R, Imai K. Bmf is a possible mediator in histone deacetylase inhibitors FK228 and CBHA-induced apoptosis. Cell Death Differ.13,129–140. (2006).
  Medline CASGoogle Scholar
• 104  Zhao Y, Tan J, Zhuang L, Jiang X, Liu ET, Yu Q. Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim. Proc. Natl Acad. Sci. USA102,16090–16095 (2005).
  Medline CASGoogle Scholar
• 105  Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev. Drug Discov.1,287–299 (2002).
  Medline CASGoogle Scholar
• 106  Insinga A, Monestiroli S, Ronzoni S et al. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat. Med.11,71–76 (2005).
  Medline CASGoogle Scholar
• 107  Borbone E, Berlingieri MT, De Bellis F et al. Histone deacetylase inhibitors induce thyroid cancer-specific apoptosis through proteasome-dependent inhibition of TRAIL degradation. Oncogene29,105–116 (2010).
  Medline CASGoogle Scholar
• 108  D’Acunto CW, Carratu A, Rodriquez M, Taddei M, Parente L, Petrella A. LGP1, a histone deacetylase inhibitor analogue of FR235222, sensitizes promyelocytic leukaemia U937 cells to TRAIL-mediated apoptosis. Anticancer Res.30,887–894 (2010).
  MedlineGoogle Scholar
• 109  Petrella A, Festa M, Ercolino SF et al. Annexin-1 downregulation in thyroid cancer correlates to the degree of tumour differentiation. Cancer Biol. Ther.5,643–647 (2006).
  Medline CASGoogle Scholar
• 110  Garcia Pedrero JM, Fernandez MP, Morgan RO et al. Annexin A1 down-regulation in head and neck cancer is associated with epithelial differentiation status. Am. J. Pathol.,164,73–79 (2004).
  MedlineGoogle Scholar
• 111  D’Acunto CW, Fontanella B, Rodriquez M, Taddei M, Parente L, Petrella A. Histone deacetylase inhibitor FR235222 sensitizes human prostate adenocarcinoma cells to apoptosis through up-regulation of Annexin A1. Cancer Lett.295,85–91 (2010).
  MedlineGoogle Scholar
• 112  Petrella A, D’Acunto CW, Rodriquez M et al. Effects of FR23S222, a novel HDAC inhibitor, in proliferation and apoptosis of human leukaemia cell lines: role of annexin A1. Eur. J. Cancer44,740–749 (2008).
  Medline CASGoogle Scholar
• 113  Xu W, Ngo L, Perez G, Dokmanovic M, Marks PA. Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor. Proc. Natl Acad. Sci. USA103,15540–15545 (2006).
  Medline CASGoogle Scholar
• 114  Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene26,5541–5552 (2007).
  Medline CASGoogle Scholar
• 115  Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK, Benz CC. Clinical development of histone deacetylase inhibitors as anticancer agents. Annu. Rev. Pharmacol. Toxicol.45,495–528 (2005).
  Medline CASGoogle Scholar
• 116  Atadja PW. HDAC inhibitors and cancer therapy, epigenetics and disease. Prog. Drug Res.67,175–195 (2011).▪ An update monograph on the role of HDACs in protumorigenic mechanisms and on the current developmental status and prospects for their inhibitors in cancer therapy.
  Medline CASGoogle Scholar
• 117  Cimini D, Mattiuzzo M, Torosantucci L, Degrassi F. Histone hyperacetylation in mitosis prevents sister chromatid separation and produces chromosome segregation defects. Mol. Biol. Cell14,3821–3833 (2003).
  Medline CASGoogle Scholar
• 118  Taddei A, Maison C, Roche D, Almouzni G. Reversible disruption of pericentric heterochromatin and centromere function by inhibiting deacetylases. Nat. Cell. Biol.3,114–120 (2001).
  Medline CASGoogle Scholar
• 119  Dowling M, Voong KR, Kim M, Keutmann MK, Harris E, Kao GD. Mitotic spindle checkpoint inactivation by trichostatin a defines a mechanism for increasing cancer cell killing by microtubule-disrupting agents. Cancer Biol. Ther.4,197–206 (2005).
  Medline CASGoogle Scholar
• 120  Robbins AR, Jablonski SA, Yen TJ et al. Inhibitors of histone deacetylases alter kinetochore assembly by disrupting pericentromeric heterochromatin. Cell Cycle4,717–726 (2005).
  Medline CASGoogle Scholar
• 121  Ruefli AA, Ausserlechner MJ, Bernhard D et al. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc. Natl Acad. Sci. USA98,10833–10838 (2001).
  Medline CASGoogle Scholar
• 122  Rosato RR, Almenara JA, Grant S. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res.63,3637–3645 (2003).
  Medline CASGoogle Scholar
• 123  Ellis L, Hammers H, Pili R. Targeting tumor angiogenesis with histone deacetylase inhibitors. Cancer Lett.280,145–153 (2009).
  Medline CASGoogle Scholar
• 124  Jeong JW, Bae MK, Ahn MY et al. Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell111,709–720 (2002).
  Medline CASGoogle Scholar
• 125  Deroanne CF, Bonjean K, Servotte S et al. Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene21,427–436 (2002).
  Medline CASGoogle Scholar
• 126  Carew JS, Giles FJ, Nawrocki ST. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett.269,7–17 (2008).▪ Summarizes the different mechanisms of HDACi-induced apoptosis and discuss their use in combination with other anticancer agents.
  Medline CASGoogle Scholar
• 127  Liang D, Kong X, Sang N. Effects of histone deacetylase inhibitors on HIF-1. Cell Cycle5,2430–2435 (2006).
  Medline CASGoogle Scholar
• 128  Kong X, Lin Z, Liang D, Fath D, Sang N, Caro J. Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor1 alpha. Mol. Cell. Biol.26,2019–2028 (2006).
  Medline CASGoogle Scholar
• 129  Qian DZ, Kachhap SK, Collis SJ et al. Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha. Cancer Res.66,8814–8821 (2006).
  Medline CASGoogle Scholar
• 130  Naldini A, Filippi I, Cini E, Rodriquez M, Carraro F, Taddei M. Downregulation of Hypoxia-related Responses by Novel Antitumor Histone Deacetylase Inhibitors in MDAMB231 Breast Cancer Cells. Anticancer Agents Med. Chem.12(4), 407–413 (2011).
  Google Scholar
• 131  Kim SO, Choi BT, Choi I-W et al. Anti-invasive activity of histone deacetylase inhibitors via the induction of Egr-1 and the modulation of tight junction-related proteins in human hepatocarcinoma cells. BMB Reports42,655–660 (2009).
  Medline CASGoogle Scholar
• 132  Qureshi IA, Mehler MF. Epigenetics, nervous system tumors, and cancer stem cells. Cancers3,3525–3556 (2011).
  Medline CASGoogle Scholar
• 133  Farrell A. A close look at cancer. Nat. Med.17,262–265 (2011).
  Medline CASGoogle Scholar
• 134  Marks PA, Xu WS. Histone deacetylase inhibitors: potential in cancer therapy. J. Cell. Biochem.107,600–608 (2009).
  Medline CASGoogle Scholar
• 135  Haberland M, Montgomery RL, Olson EN. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat. Rev. Genet.10,32–42 (2009).▪ Focuses on the relationship between the crucial roles of HDACs in numerous biological processes and on the regulation of gene expression. With interesting analysis on the use of HDAC knockout mice.
  Medline CASGoogle Scholar
• 136  Wagner JM, Hackanson B, Lübbert M, Jung M. Therapy in combination. Clin. Epigenet.1,117–136 (2010).
  Medline CASGoogle Scholar
• 137  Wang H, Dymock BW. New patented histone deacetylase inhibitors. Expert Opin. Ther. Pat.19,1727–1757 (2009).
  Medline CASGoogle Scholar
• 138  Suzuki T. Explorative study on isoform-selective histone deacetylase inhibitors. Chem. Pharm. Bull.57,897–906 (2009).
  Medline CASGoogle Scholar
• 139  Ma X, Ezzeldin HH, Diasio RB. Histone deacetylase inhibitors: current status and overview of recent clinical trials. Drugs69,1911–1934 (2009).
  Medline CASGoogle Scholar
• 140  Bantscheff M, Hopf C, Savitski M et al. Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nat. Biotechnol.29,255–265 (2011).▪▪ Describes the interaction of small molecules with megadalton protein complexes (cluster) and the discovery of novel targets and inhibitors. Concludes that the selectivity of HDACis should be evaluated in the context of HDAC complexes and not purified catalytic subunits.
  Medline CASGoogle Scholar
• 141  La Thangue NB, Kerr DJ. Predictive biomarkers: a paradigm shift towards personalized cancer medicine. Nat. Rev. Clin. Oncol.8,587–596 (2011).
  Medline CASGoogle Scholar
• 142  Fotheringham S, Epping MT, Stimson L et al. Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis. Cancer Cell15,57–66 (2009).
  Medline CASGoogle Scholar
• 143  Khan O, Fotheringham S, Wood V et al. HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy. Proc. Natl Acad. Sci. USA107,6532–6537 (2010).
  Medline CASGoogle Scholar
• 144  Jennifer LB,Yongyao X, Susanne JS et al. Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function. Blood109,1123–1130 (2007).
  MedlineGoogle Scholar
• 145  Adcock IM. HDAC inhibitors as anti-inflammatory agents. Br. J. Pharmacol.150,829–831 (2007).
  Medline CASGoogle Scholar
• 146  Routy JP. Valproic acid: a potential role in treating latent HIV infection. Lancet366,523–524 (2005).
  MedlineGoogle Scholar
• 147  Andrews KT, Haque A, Jones MK. HDAC inhibitors in parasitic diseases. Immunol. Cell Biol.90,66–77 (2012).
  Medline CASGoogle Scholar
• 148  Fischer A, Sananbenesi F, Wang X, Dobbin M, Tsai L-H. Recovery of learning and memory is associated with chromatin remodelling. Nature447,178–182 (2007).
  Medline CASGoogle Scholar
• 149  Chuang D-M, Leng Y, Marinova Z, Kim H-J, Chiu C-T. Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends Neurosci.32,591–601 (2009).
  Medline CASGoogle Scholar
• 150  Butler R, Bates GP. Histone deacetylase inhibitors as therapeutics for polyglutamine disorders. Nat. Rev. Neurosci.7,784–796 (2006).
  Medline CASGoogle Scholar
• 151  Cao H, Jung M, Stamatoyannopoulos G. Hydroxamide derivatives of short chain fatty acid have erythropoietic activity and induce γ-gene expression in vivo. Exp. Hematol.33,1443–1449 (2005).
  Medline CASGoogle Scholar
• 152  Minetti GC, Colussi C, Adami R et al. Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors. Nat. Med.12,1147–1150 (2006).
  Medline CASGoogle Scholar
• 153  Lin HS, Hu CY, Chan HY et al. Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. Br. J. Pharmacol.150,862–872 (2007).
  Medline CASGoogle Scholar
• 154  Romagnani P, Lasagni L, Mazzinghi B, Lazzeri E, Romagnani S. Pharmacological modulation of stem cell function. Curr. Med. Chem.14,1129–1139 (2007).
  Medline CASGoogle Scholar
• 155  Khan O, La Thangue NB. HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol. Cell Biol.90,85–94 (2012).▪ Up-to-date review on the mechanism of HDACis, with a selection of non-histone proteins that are known to be direct substrates for HDAC enzymes. A comment on the role of biomarkers, and the clinical applications of the two US FDA-approved HDACis, complete this review.
  Medline CASGoogle Scholar
• 201  RCSB Protein Data Bank. www.rcsb.org/pdb/explore.do?structureId=1t69
  Google Scholar
• 202  Clinicaltrials.gov. www.clinicaltrials.gov
  Google Scholar